S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in
NASDAQ:OGI

OrganiGram Stock Forecast, Price & News

$3.08
-0.28 (-8.33 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.04
Now: $3.08
$3.43
50-Day Range
$1.58
MA: $2.50
$6.00
52-Week Range
$1.01
Now: $3.08
$6.45
Volume15.75 million shs
Average Volume30.95 million shs
Market Capitalization$715.39 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co., ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
OrganiGram logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OGI
CUSIPN/A
CIKN/A
Phone1-855-961-9420
Employees516
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.61 million
Cash Flow$0.03 per share
Book Value$1.04 per share

Profitability

Net Income$-101,290,000.00
Net Margins-207.26%

Miscellaneous

Market Cap$715.39 million
Next Earnings Date4/13/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.18 out of 5 stars

Medical Sector

854th out of 1,957 stocks

Pharmaceutical Preparations Industry

419th out of 771 stocks

Analyst Opinion: 2.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$3.08
-0.28 (-8.33 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OGI News and Ratings via Email

Sign-up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OrganiGram (NASDAQ:OGI) Frequently Asked Questions

Is OrganiGram a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OrganiGram stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGI, but not buy additional shares or sell existing shares.
View analyst ratings for OrganiGram
or view top-rated stocks.

What stocks does MarketBeat like better than OrganiGram?

Wall Street analysts have given OrganiGram a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OrganiGram wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, April 13th 2021.
View our earnings forecast for OrganiGram
.

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) issued its earnings results on Monday, November, 30th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The firm earned $15.19 million during the quarter, compared to the consensus estimate of $14.77 million. OrganiGram had a negative net margin of 207.26% and a negative trailing twelve-month return on equity of 10.00%.
View OrganiGram's earnings history
.

How has OrganiGram's stock price been impacted by COVID-19?

OrganiGram's stock was trading at $1.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OGI stock has increased by 79.1% and is now trading at $3.08.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OGI?

12 analysts have issued 1 year price targets for OrganiGram's shares. Their forecasts range from $1.72 to $4.25. On average, they expect OrganiGram's stock price to reach $2.93 in the next year. This suggests that the stock has a possible downside of 4.9%.
View analysts' price targets for OrganiGram
or view top-rated stocks among Wall Street analysts.

Who are OrganiGram's key executives?

OrganiGram's management team includes the following people:
  • Mr. Gregory Engel, CEO & Director (Age 56)
  • Mr. Derrick W. West CPA, CPA, (CA), Chief Financial Officer (Age 54)
  • Mr. Matt Rogers, Sr. VP of Operations
  • Ms. Helen Martin, Sr. VP of Strategic & Legal Affairs and Company Sec. (Age 43)
  • Mr. Paolo De Luca C.A., C.F.A, Chief Strategy Officer (Age 48)
  • Amy Schwalm, VP of Investor Relations
  • Mr. Timothy Emberg, Sr. VP of Sales & Commercial Operations
  • Mr. James Cavanagh, Chief of Staff
  • Mr. Larry Rogers, VP of International Bus. Devel.
  • Mr. Peter R. Hanson, Director of Fin.

Who are some of OrganiGram's key competitors?

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), The Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), Cannabics Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ETF Managers Group LLC (8.48%), Renaissance Technologies LLC (0.76%), Penserra Capital Management LLC (0.27%), Swiss National Bank (0.22%), AdvisorShares Investments LLC (0.13%) and Vontobel Holding Ltd. (0.11%).

Which institutional investors are selling OrganiGram stock?

OGI stock was sold by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, and Ancora Advisors LLC.

Which institutional investors are buying OrganiGram stock?

OGI stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, ETF Managers Group LLC, Penserra Capital Management LLC, Vontobel Holding Ltd., Apollon Wealth Management LLC, Swiss National Bank, Meitav Dash Investments Ltd., and Credit Suisse AG.

How do I buy shares of OrganiGram?

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $3.08.

How much money does OrganiGram make?

OrganiGram has a market capitalization of $715.39 million and generates $64.61 million in revenue each year. The company earns $-101,290,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does OrganiGram have?

OrganiGram employs 516 workers across the globe.

What is OrganiGram's official website?

The official website for OrganiGram is www.organigram.ca.

Where are OrganiGram's headquarters?

OrganiGram is headquartered at 35 English Dr., Moncton Z4, E1E 3X3.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.